PMF1 Antibody

What is PMF1 and what is its biological significance in cellular function?

PMF1 (Polyamine-modulated factor 1) is a multifunctional protein involved in critical cellular processes including chromosome segregation, transcriptional regulation, and genomic stability. It is part of the MIS12 complex which is essential for normal chromosome alignment and segregation and kinetochore formation during mitosis . Additionally, PMF1 may function as a cotranscription partner of NFE2L2 involved in regulation of polyamine-induced transcription of SSAT .

The protein is localized in multiple cellular compartments including the cytosol, Golgi apparatus, kinetochore, and nucleoplasm . It enables leucine zipper domain binding and transcription coactivator activity . Recent research has implicated PMF1 dysregulation in several pathological conditions, including bladder carcinoma and urinary bladder cancer .

PMF1 has a calculated molecular weight of approximately 19 kDa, though it is typically observed at 23-26 kDa in experimental conditions due to post-translational modifications .

Proper storage and handling are critical for maintaining antibody performance:

Researchers should note that some PMF1 antibody preparations may contain small amounts of BSA (0.1% or 0.05%) , which should be considered when designing experiments where BSA might interfere.

How can researchers optimize Western blot protocols for PMF1 detection?

Optimizing Western blot protocols for PMF1 requires attention to several technical details:

• Sample preparation:

  • Validated in multiple cell lines including Jurkat, HepG2, HeLa, A-549, C6, Raw264.7, and NIH/3T3

  • Protein loading: 10-20 μg of whole cell lysate is typically sufficient

• Blocking conditions:

  • Recommended blocking buffer: 5% non-fat dry milk (NFDM) in TBST

  • Blocking time: Typically 1 hour at room temperature

• Antibody dilution:

  • Primary antibody: 1:500-1:2000 in blocking buffer

  • Secondary antibody: Anti-Rabbit IgG (HRP), typically at 1:1000-1:10000 dilution

• Expected results:

  • Predicted molecular weight: 23 kDa

  • Observed molecular weight: Often appears at 23-26 kDa band

  • Exposure time: Optimally between 30 seconds to 3 minutes depending on signal strength

• Troubleshooting:

  • If multiple bands appear, consider using cell/tissue-specific positive controls like Jurkat or HepG2 cells

  • For weak signals, extend exposure time or increase antibody concentration

  • For high background, increase washing steps or reduce antibody concentration

What are the key considerations for immunohistochemistry applications with PMF1 antibodies?

For successful immunohistochemistry using PMF1 antibodies:

• Tissue preparation:

  • Validated in human tissues including gliomas tissue

  • Fixation: Standard formalin fixation and paraffin embedding is compatible

• Antigen retrieval:

  • Primary recommendation: TE buffer pH 9.0

  • Alternative method: Citrate buffer pH 6.0

  • Heat-induced epitope retrieval methods are typically most effective

• Antibody concentration:

  • Recommended dilution range: 1:50-1:500

  • Optimal dilution may vary by tissue type and detection system

• Detection systems:

  • Compatible with standard HRP/DAB detection systems

  • Also compatible with fluorescent secondary antibodies for immunofluorescence applications

• Controls:

  • Positive tissue controls: Human gliomas tissue has been validated

  • Negative controls: Primary antibody omission and isotype controls are recommended

How do different PMF1 antibody types compare in experimental performance?

PMF1 antibodies are available in different formats with varying performance characteristics:

When selecting between antibody types, researchers should consider:

• The primary application (detection vs. quantification)

• Required specificity and sensitivity

• Importance of batch-to-batch consistency

• Reagent budget constraints

What controls should be implemented when using PMF1 antibodies for research?

Proper experimental controls are essential for reliable PMF1 antibody-based research:

• Positive controls:

  • Cell lines: Jurkat, HepG2, and HeLa cells consistently express detectable levels of PMF1

  • Tissues: Human gliomas tissue has been validated for IHC applications

• Negative controls:

  • Primary antibody omission: Replaces primary antibody with buffer alone

  • Isotype control: Use of non-targeting antibody of same isotype (e.g., Rabbit IgG monoclonal [EPR25A] for PMF1 rabbit monoclonal antibodies)

  • Blocking peptide: When available, pre-incubation of antibody with immunizing peptide should abolish specific signal

• Validation strategies:

  • Knockdown/knockout validation: siRNA or CRISPR-based depletion of PMF1

  • Orthogonal detection: Confirmation with alternative antibodies targeting different epitopes

  • Mass spectrometry validation: For IP applications, MS confirmation of pulled-down proteins

• Technical controls:

  • Loading controls: For Western blot, include housekeeping proteins (β-actin, GAPDH)

  • Standardized sample preparation: Consistent lysis and handling procedures

  • Replicate experiments: Multiple biological and technical replicates

How can PMF1 antibodies be used to investigate the MIS12 complex and kinetochore biology?

PMF1 is an integral component of the MIS12 complex, which plays a critical role in kinetochore assembly and chromosome segregation during mitosis . Researchers can use PMF1 antibodies to:

• Co-immunoprecipitation studies:

  • PMF1 antibodies have been validated for IP applications and can be used to pull down the entire MIS12 complex

  • Protocol optimization: Use of low-detergent buffers (0.1-0.5% NP-40 or Triton X-100) helps maintain complex integrity

  • Verification: Western blot for other MIS12 complex components (MIS12, NSL1, DSN1) after PMF1 IP

• Chromatin immunoprecipitation (ChIP):

  • Though not explicitly validated in the provided data, PMF1 antibodies may be adapted for ChIP to study kinetochore-chromatin interactions

  • Crosslinking optimization: Both formaldehyde (1%) and DSG/formaldehyde dual crosslinking approaches should be tested

  • Sonication parameters: Careful optimization to preserve protein complexes while fragmenting chromatin

• Immunofluorescence microscopy:

  • PMF1 antibodies can be used to visualize kinetochore structures during different cell cycle phases

  • Co-staining with centromere markers (e.g., CENP proteins) or other kinetochore components

  • Cell synchronization protocols (e.g., double thymidine block) can enrich for mitotic cells

• Live-cell imaging:

  • For dynamic studies, consider generating cell lines expressing fluorescently-tagged PMF1 and validating localization with antibodies

What approaches can be used to study PMF1's role in transcriptional regulation?

Beyond its role in kinetochore function, PMF1 may act as a cotranscription partner of NFE2L2 involved in regulating polyamine-induced transcription . To investigate this function:

• Chromatin immunoprecipitation followed by sequencing (ChIP-seq):

  • Optimize ChIP protocol with PMF1 antibodies for genome-wide binding site analysis

  • Bioinformatic analysis should include motif discovery and comparison with known NFE2L2 binding sites

  • Integration with transcriptome data to correlate binding with gene expression changes

• Co-immunoprecipitation studies:

  • Use PMF1 antibodies to identify transcriptional complex components

  • Reciprocal IP with NFE2L2 antibodies to confirm interaction

  • Treatment conditions: Consider polyamine modulation (e.g., spermidine or spermine supplementation)

• Reporter gene assays:

  • Construct luciferase reporters driven by promoters of potential target genes

  • Measure reporter activity after PMF1 overexpression or knockdown

  • Verify protein expression changes by Western blot with PMF1 antibodies

• Proximity ligation assay (PLA):

  • Combine PMF1 antibodies with antibodies against suspected interaction partners

  • Visualize protein-protein interactions in situ at transcriptionally active regions

How can PMF1 antibodies contribute to cancer research, particularly in bladder carcinoma studies?

PMF1 has been implicated in bladder carcinoma and urinary bladder cancer . Researchers investigating this connection can utilize PMF1 antibodies in several ways:

• Tissue microarray (TMA) analysis:

  • IHC staining of bladder cancer TMAs with PMF1 antibodies (1:50-1:200 dilution)

  • Correlation of expression levels with clinical outcomes and pathological features

  • Multiplex IHC to study co-expression with other cancer biomarkers

• Cancer cell line studies:

  • Western blot analysis of PMF1 expression across bladder cancer cell lines

  • Compare expression and localization in normal urothelial cells versus cancerous lines

  • Functional studies combining PMF1 knockdown with antibody-based detection of resulting changes

• Patient-derived xenograft (PDX) models:

  • Monitor PMF1 expression in PDX models using antibody-based techniques

  • Evaluate changes in expression following treatment interventions

  • Correlate with tumor growth and response to therapy

• Liquid biopsy development:

  • Explore potential of PMF1 as a circulating biomarker

  • Develop sensitive immunoassays using PMF1 antibodies for detection in patient samples

What are common challenges when working with PMF1 antibodies and how can they be addressed?

Despite careful planning, researchers may encounter challenges when working with PMF1 antibodies:

• Weak or absent signal in Western blot:

  • Increase antibody concentration (try 1:500 instead of 1:1000)

  • Extend primary antibody incubation (overnight at 4°C)

  • Increase protein loading (up to 30-50 μg)

  • Try alternative detection systems (e.g., more sensitive ECL substrates)

  • Verify sample preparation (ensure PMF1 is not degraded during lysis)

• High background in immunostaining:

  • Increase blocking time or concentration (try 5% BSA instead of NFDM)

  • Reduce primary antibody concentration

  • Add 0.1-0.3% Triton X-100 to antibody diluent

  • Increase washing duration and number of washes

  • Use species-specific secondary antibodies with minimal cross-reactivity

• Multiple bands in Western blot:

  • Verify expected molecular weight (PMF1 should appear around 23-26 kDa)

  • Test different lysis buffers to reduce protein degradation

  • Include protease inhibitors in all preparation steps

  • Consider post-translational modifications or isoforms

• Inconsistent IP results:

  • Optimize antibody amount (typically 2-5 μg per IP reaction)

  • Test different IP buffers (varying salt and detergent concentrations)

  • Pre-clear lysates thoroughly to reduce non-specific binding

  • Consider crosslinking antibody to beads to prevent antibody co-elution

How can researchers validate the specificity of PMF1 antibodies?

Antibody specificity is crucial for reliable research results. To validate PMF1 antibodies:

• Genetic approaches:

  • siRNA knockdown: Reduction in PMF1 protein should correspond to reduced antibody signal

  • CRISPR/Cas9 knockout: Complete loss of specific signal in knockout cells

  • Overexpression: Increased signal intensity in cells overexpressing PMF1

• Peptide competition:

  • Pre-incubate antibody with immunizing peptide or recombinant PMF1 protein

  • Specific signals should be blocked while non-specific signals remain

  • Include positive control (untreated antibody) and negative control (non-specific peptide)

• Cross-validation with multiple antibodies:

  • Test multiple PMF1 antibodies targeting different epitopes

  • Consistent results across antibodies suggest specific detection

  • Consider both monoclonal and polyclonal antibodies for comprehensive validation

• Orthogonal methods:

  • Confirm PMF1 expression with non-antibody methods (e.g., RNA-seq, qPCR)

  • Mass spectrometry validation of immunoprecipitated proteins

  • in situ hybridization to correlate protein and mRNA localization

How should researchers select the optimal PMF1 antibody for specific experimental contexts?

The choice of PMF1 antibody should be guided by the specific research context and experimental requirements:

• Application-specific considerations:

  • Western blot: Both polyclonal and monoclonal antibodies perform well, with recommended dilutions of 1:500-1:2000

  • IHC/IF: Select antibodies specifically validated for these applications, using recommended dilutions (1:50-1:500)

  • IP: Monoclonal antibodies often provide cleaner results; look for antibodies specifically validated for IP

  • ChIP: If available, choose antibodies validated for chromatin applications

• Species-specific considerations:

  • Human research: Most PMF1 antibodies have been validated with human samples

  • Mouse/rat research: Select antibodies with demonstrated cross-reactivity (e.g., products tested in C6, Raw264.7, NIH/3T3 cells)

  • Sequence homology: Consider antibodies raised against conserved epitopes for cross-species applications

• Technical factors:

  • Epitope accessibility: For fixed tissues, antibodies targeting more accessible epitopes are preferred

  • Application compatibility: Some antibodies perform better in native conditions versus denatured

  • Buffer compatibility: Consider potential interference from buffer components (detergents, reducing agents)

• Experimental controls:

  • Availability of knockout/knockdown systems for validation

  • Access to competing peptides for blocking experiments

  • Availability of positive and negative control samples

How are new technologies enhancing PMF1 antibody applications in research?

Emerging technologies are expanding the potential applications of PMF1 antibodies:

• Super-resolution microscopy:

  • PMF1 antibodies can be used with techniques like STORM, PALM, or STED to visualize kinetochore structures at nanoscale resolution

  • These approaches can reveal previously undetectable PMF1 distribution patterns and protein-protein interactions

• Multiplex imaging:

  • Techniques like Imaging Mass Cytometry or CODEX allow simultaneous detection of dozens of proteins

  • PMF1 antibodies can be metal-tagged for multiplexed analysis with other kinetochore components

  • These approaches enable comprehensive analysis of PMF1 in complex cellular structures

• Single-cell proteomics:

  • PMF1 antibodies can be incorporated into single-cell Western blot or single-cell proteomics workflows

  • These techniques allow correlation of PMF1 expression with individual cell phenotypes

  • Particularly valuable for studying heterogeneous cancer cell populations

• Engineered antibody formats:

  • Development of nanobodies or single-chain antibody fragments against PMF1

  • These smaller formats may offer improved access to sterically hindered epitopes

  • Potential for intracellular expression to track PMF1 in living cells

What are promising research directions for PMF1 antibodies in understanding disease mechanisms?

Beyond current applications, PMF1 antibodies hold potential for advancing disease-related research:

• Cancer biology:

  • Exploration of PMF1's potential as a biomarker in bladder cancer and other malignancies

  • Investigation of PMF1's role in chromosomal instability and aneuploidy in cancer

  • Studies of PMF1's transcriptional regulation functions in oncogenic pathways

• Neurodegenerative diseases:

  • While not directly implicated, PMF1's role in genomic stability may be relevant to neurodegeneration

  • PMF1 antibodies could help explore potential connections to disease mechanisms

• Development of therapeutic approaches:

  • PMF1 antibodies could help validate PMF1 as a potential therapeutic target

  • Screening for compounds that modulate PMF1 expression or function

• Reproductive biology:

  • Given PMF1's role in chromosome segregation, investigating its function in meiosis and fertility

  • PMF1 antibodies could help explore mechanisms of chromosomal abnormalities in gametes